Deans' stroke musings: EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, September 25, 2025

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

FYI. Ask your competent? doctor how they are supporting getting this approved in the US. DOING NOTHING; FIRE THEM!

EMA Approves Semaglutide as First GLP-1 RA for Cardiovascular, Stroke-Related Benefits

Novo Nordisk's semaglutide gains EU approval as the first oral GLP-1 RA to reduce cardiovascular risks in type 2 diabetes patients.According to a new announcement, the European Medicines Agency’s Committee for Medicinal Products for Human Use has approved an update to semaglutide’s (Rybelsus; Novo Nordisk) label, allowing the glucagon-like peptide 1 receptor agonist (GLP-1 RA) to be used to reduce cardiovascular death, heart attack, and stroke. With the decision, it becomes the first GLP-1 RA approved in the European Union for type 2 diabetes with a proven cardiovascular benefit. Semaglutide, marketed as Ozempic in the United States and Rybelsus in Europe, became the first and only oral GLP-1 RA approved for the treatment of type 2 diabetes in 2019. This latest indication is based on data from the phase 3 SOUL trial (NCT03914326), in which treatment with the GLP-1 RA reduced cardiovascular death, heart attack, and stroke by 14% vs. placebo when added to the standard of care in adults with type 2 diabetes at high cardiovascular risk. "Heart problems are the leading cause of disability and death for people living with type 2 diabetes. Therefore, treatments that also address heart problems are key to improving not only health outcomes, but also quality of life—and this approval will help do just that," Emil Kongshøj Larsen, executive vice president, international operations at Novo Nordisk, said in a statement.¹ "This milestone makes semaglutide the only oral GLP-1 RA with proven blood glucose and body weight reduction, as well as cardiovascular benefits."